Patents Examined by Kamal Saeed
  • Patent number: 11191747
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: December 7, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
  • Patent number: 11192861
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: December 7, 2021
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • Patent number: 11179371
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 23, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Robert Augustin, Sebastian Bandholtz, Sara Frattini, Bernd Wellenzohn
  • Patent number: 11180488
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C3-8 cycl
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 23, 2021
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
  • Patent number: 11174219
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Patent number: 11174238
    Abstract: Disclosed are enantioselective cross dehydrogenative coupling reactions for synthesizing tetrahydropyran compounds. Novel tetrahydropyran compounds may be synthesized by the disclosed methods as well as tetrahydropyran precursor compounds for synthesizing various naturally occurring compounds. The enantioselective cross dehydrogenative coupling reactions utilize in situ Lewis Acid activation in combination with oxidative formation of an oxocarbenium ion to provide a highly efficient and selective coupling reaction for synthesizing tetrahydropyran compounds.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: November 16, 2021
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Ansoo Lee, Richard C. Betori
  • Patent number: 11168093
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 9, 2021
    Assignee: Celgene Corporation
    Inventors: Kurt Armbrust, Fedor Romanov Michailidis, Karin Irmgard Worm, John Michael Ellis
  • Patent number: 11168080
    Abstract: This application is directed to inhibitors of dynamin-1-like protein (Drp1) represented by the following structural formula (I): and methods for their use, such as to treat one or more DRP1-related diseases.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: Mitobridge, Inc.
    Inventors: Nan Ji, Jeyaprakash Narayanan Seenisamy
  • Patent number: 11161840
    Abstract: The present invention relates to a process for producing compounds of formula (I) in which R1, A, X and Z are as defined in the description by reaction of compounds of formula (II) or salts thereof with 2-chloro-5-chloromethylpyridine in a nonpolar aliphatic or aromatic solvent, preferably in the presence of a phase transfer catalyst.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 2, 2021
    Assignee: Bayer CropScience Aktiengesellschaft
    Inventors: Stefan Antons, Martin Littmann, Joerg Schulz, Wahed Ahmed Moradi, Thomas Geller
  • Patent number: 11161821
    Abstract: The present invention relates to an improved process for the purification of Eltrombopag olamine of compound of formula (2). The present invention also relates to an improved process for the preparation of Eltrombopag olamine intermediates and further conversion to Eltrombopag olamine of a compound of formula (2).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: November 2, 2021
    Assignee: Aurobindo Pharma Ltd.
    Inventors: Moturu Venkata Ramakrishna Murthy, Tiwari Shashi Kant, Nadakudity Sailendra Kumar, Samala Bhanuchander, Rajesh Chennuri, Srinivasa Chary Katuroju, Sivakumaran Meenakshisunderam
  • Patent number: 11155522
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 26, 2021
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall
  • Patent number: 11149010
    Abstract: Provided are producing methods for a 3-difluoromethylpyrazole compound and a 3-difluoromethylpyrazole-4-carboxylic acid compound, which include, in a reaction solvent containing a specific solvent, subjecting a difluoroacetyl group-containing compound, a hydrazine compound, and formaldehyde to a cyclocondensation reaction, and subsequently oxidizing the obtained pyrazole compound precursor, and a pyrazolidine compound represented by a specific formula in these producing methods.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: October 19, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Takayuki Ito
  • Patent number: 11147813
    Abstract: The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: (I).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 19, 2021
    Assignee: Autifony Therapeutics Limited
    Inventors: Charles Large, Giuseppe Alvaro
  • Patent number: 11142497
    Abstract: An object of the present invention is to provide a novel plant growth inhibiting agent and a plant growth inhibiting method using the same. The plant growth inhibiting agent of the present invention comprises, as an active ingredient, a compound represented by the following formula (I?) and/or a salt thereof. In the formula (I?), R1a represents a substituted or unsubstituted C1 to C20 alkyl group, a substituted or unsubstituted C6 to C14 aryl group, a substituted or unsubstituted C3 to C13 heteroaryl group, or the like; R2 represents a substituted or unsubstituted C1 to C20 alkylene group, a substituted or unsubstituted C6 to C14 arylene group, or the like; R3a represents OH, a substituted or unsubstituted C1 to C6 alkoxy group, or the like; X represents an oxygen atom; Y represents a substituent; q represents any integer of 0 to 3; n represents 0 or 1; and m represents 0 or 1.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: October 12, 2021
    Assignees: National University Corporation Kumamoto University, Nippon Soda Co., Ltd.
    Inventors: Hayato Ishikawa, Tokio Tani, Shinichiro Sawa, Takashi Ishida, Yusuke Fukushima, Jun Inagaki
  • Patent number: 11142536
    Abstract: Macromolecules comprising triazoles and related compositions and methods are provided. In some embodiments, a macromolecule may comprise one or more repeat units including a triazole and a functionalizable pendant group. The macromolecule may also comprise one or more orthogonally addressable end groups. In some embodiments, one or more repeat units may be formed by a synthetic process that allows for precise control over stereochemistry, pendant functionality, and/or the spatial relationship (e.g., distance) between groups in the repeat unit(s). Such precise control over pendant group and repeat unit structure allows for the macromolecule functionality, stereochemistry, and spacing between groups (e.g., pendant groups) to be precisely controlled. Macromolecules described herein may be used for a wide variety of applications, including the delivery of active agents.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 12, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Jeremiah A. Johnson, Yoshiki Shibuya, Hung Vanthanh Nguyen, Yivan Jiang
  • Patent number: 11135205
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 5, 2021
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
  • Patent number: 11123315
    Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: September 21, 2021
    Assignee: Propella Therapeutics, Inc.
    Inventors: Philip J. Birbara, Daniel Bucks
  • Patent number: 11124502
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 21, 2021
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Patent number: 11117888
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 14, 2021
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Patent number: 11116751
    Abstract: The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: September 14, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chan Mi Joung, Sun Gwan Hwang, Ji Won Lee, Young Koo Jang